Home Companies Catalysts Deep Dives
Fasenra benralizumab APPROVED
Drug Profile
ModalityAntibody
RouteSC
Therapy AreaR&I
Launch2017-11-14
US LOE2029-11-14
Peak Sales Est$2500M
Formulations[{"id":"fasenra-sc","doses":"30mg","route":"SC","device":"Pre-filled syringe/autoinjector","setting"
Companies
AZN (ORIGINATOR)100%
Mechanism: IL-5 receptor antagonist
Expert: Afucosylated humanized IgG1 monoclonal antibody targeting IL-5Rα that induces antibody-dependent cell-mediated cytotoxicity of eosinophils.
Everyday: Reduces eosinophils (a type of white blood cell) that cause inflammation in severe asthma.
Targets: ["IL-5R"]
Revenue History
PeriodRevenue ($M)
2023$1,642M
2024$1,821M
Q1 2025$490M
Q2 2025$510M
Programs (2)
IndicationStageKey StudyRegional Status
EGPAAPPROVEDMANDARA[{"stage":"APPROVED","region":"US","approval_date":"2024-09-18"}]
Sev eos asthmaAPPROVEDSIROCCO[{"stage":"APPROVED","region":"US","approval_date":"2017-11-14"},{"stage":"APPRO
Notes
IL-5 receptor antibody for asthma.
Data from Supabase · Updated 2026-03-24